




PATENT  
ATTORNEY DOCKET NO. 50164/015002

Certificate of Mailing: Date of Deposit: March 13, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alexis L. Perry

Printed name of person mailing correspondence

  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fong et al.

Art Unit: 1614

Serial No.: 10/517,639

Examiner:

Filed: June 28, 2005

Customer No.: 21559

Title: COMBINATIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a communication from a foreign patent office in a counterpart application is also enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 3/13/06

  
Michael J. Belliveau, Ph.D.  
Reg. No. 52,608

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50164/015002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/517,639
		Applicant Fong et al.
		Filing Date June 28, 2005
		Group 1614
		IDS Filed March 13, 2006
(37 C.F.R. § 1.98(b))		

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication (or Issue) Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,298,604	11-03-1981	Hammell			
	4,491,588	01-01-1985	Rosenburg et al.			
	4,569,935	02-11-1986	Rosenberg et al.			
	4,883,792	11-28-1989	Timmins et al.			
	4,942,162	07-17-1990	Rosenberg et al.			
	5,002,938	03-26-1991	Wang et al.			
	5,110,809	05-05-1992	Wang et al.			
	5,310,545	05-10-1994	Eisen			
	5,358,959	10-25-1994	Halperin et al.			
	5,407,663	04-18-1995	Eisen			
	5,432,176	07-11-1995	Walser			
	5,643,936	07-01-1997	Halperin et al.			
	5,994,341	11-30-1999	Hunter et al.			
	6,075,056	06-13-2000	Quigley, Jr. et al.			
	6,207,703	03-27-2001	Ponikau			
	2001/0031799	10-18-2001	Ponikau			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	ES 2064288	01-16-1995	Spain (with English translation)			
	WO 99/20271	04-29-1999	WIPO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



Sheet 2 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50164/015002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/517,639
		Applicant Fong et al.
		Filing Date June 28, 2005
		Group 1614
(37 C.F.R. § 1.98(b))		IDS Filed March 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
Baciewicz and Baciewicz, "Ketoconazole and Fluconazole Drug Interactions," <i>Arch. Intern. Med.</i> 153:1970-1976 (1993).	
Delbarre, "On the Possible Anti-Rheumatic Effects (Immuno-Effect?) of Imidazole Derivatives," <i>Biomedicine</i> 27:97-98 (1977).	
Faergemann, "Treatment of Sebopsoriasis with Itraconazole," <i>Mykosen</i> 28:612-618 (1985).	
Flannery et al., "Levamisole," <i>Lancet</i> 1:750-751 (1975).	
Fredriksson, "Treatment of Dermatomycoses with Topical Econazole Combined With a Steroid as Compared With a Conventional Oxichinoline-Steroid Combination," <i>Curr. Ther. Res.</i> 26:958-961 (1979).	
Hantschke and Reichenberger, "Doppelblinde, Randomisierte Vergleichende in Vivo Untersuchungen Zwischen den Antimykotika Clotrimazol, Tolnaftat und Naftifin**)"), <i>Mykosen</i> 23:657-668 (1980).	
Ludwig et al., "Steroid-Specific Effects of Ketoconazole on Corticosteroid Disposition: Unaltered Prednisolone Elimination," <i>DICP</i> 23:858-861 (1989).	
Maloley et al., "Severe Reversible Thrombocytopenia Resulting From Butoconazole Cream", <i>DICP</i> 24:143-144. 1990	
Otterness and Niblack, "Clotrimazole and Rheumatoid Arthritis," <i>Lancet</i> 1:148 (1976).	
Panayi, "Treating Rheumatoid Arthritis with Clotrimazole," <i>Nat. Med.</i> 1:977-978 (1995).	
Rosenberg et al., "Treatment of Psoriasis with Antimicrobial Agents," <i>Seminars in Dermatology</i> 4:307-311 (1985).	
Schuermans, "Levamisole in Rheumatoid Arthritis," <i>Lancet</i> 1:111 (1975).	
Smith et al., "Phospholipid Metabolism in Polymorphonuclear Leukocytes From Rheumatoid Arthritis Patients: Effects of Non-Steroidal Anti-Inflammatory Agents and Clotrimazole," <i>Int J. Immunopharmacol</i> 11:45-55 (1989).	
van der Vleuten and van der Kerkhof, "Management of Scalp Psoriasis: Guidelines for Corticosteroid Use in Combination Treatment," <i>Drugs</i> 61:1593-1598 (2001).	
Wojtulewski et al., "Clotrimazole in Rheumatoid Arthritis," <i>Ann. Rheum. Dis.</i> 39:469-472 (1980).	
Wyburn-Mason, "Clotrimazole and Rheumatoid Arthritis," <i>Lancet</i> 1:489 (1976).	
Yamashita et al., "Lack of Pharmacokinetic and Pharmacodynamic Interactions Between Ketoconazole and Prednisolone," <i>Clin. Pharmacol. Ther.</i> 49:558-570 (1991).	
Zürcher et al., "Impact of Ketoconazole on the Metabolism of Prednisolone," <i>Clin. Pharmacol. Ther.</i> 45:366-372	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/015002
		Serial No.	10/517,639
		Applicant	Fong et al.
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	June 28, 2005
		Group	1614
(37 C.F.R. § 1.98(b))		IDS Filed	March 13, 2006

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	